NEWS PROVIDED BY Sparta Biopharma, Inc.  DURHAM, N.C., March 17, 2021 /PRNewswire/ — Sparta Biomedical Inc., a developer of orthopedic solutions, today announced that its SBM-01 Biomimetic Implant has been granted a Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). SBM-01 is intended to replace damaged knee cartilage in patients having single or multiple chondral or osteochondral defects in the knee. The Breakthrough Device Program is designed to accelerate patient access to promising technologies that have the potential to provide more effective treatments for debilitating conditions. The Program provides patients and health care providers timely access to these medical … Continue reading Sparta Biomedical Receives FDA Breakthrough Device Designation for Biomimetic Implant